NCT04264143View on ClinicalTrials.gov

CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 10, 2020

Primary Completion Date

April 25, 2022

Study Completion Date

November 22, 2023

Conditions
Diffuse Intrinsic Pontine GliomaDiffuse Pontine and Thalamic GliomasDiffuse Midline Glioma
Interventions
DRUG

Infusate with MTX110 and gadolinium

Pulses 1 and 2 will be prepared with 30, 60 or 90 uM concentration of MTX110. The infusate consists of gadolinium and MTX110 (30, 60, or 90 uM) at approximately 1:100 ratio.

DEVICE

Convection-Enhanced Delivery (CED)

CED is the method by which the drug are delivered to the brain under controlled pressure to the brain by targeted micro-catheters.

Trial Locations (1)

10032

Columbia University Irving Medical Center, New York

All Listed Sponsors
collaborator

Midatech Pharma US Inc.

INDUSTRY

lead

Luca Szalontay

OTHER

NCT04264143 - CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas | Biotech Hunter | Biotech Hunter